Mostaza JM - Search Results

1

The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment.

Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X; RAP Study Group. Lahoz C, et al. Among authors: mostaza jm. Atherosclerosis. 2005 Sep;182(1):129-34. doi: 10.1016/j.atherosclerosis.2005.02.001. Epub 2005 Feb 26. Atherosclerosis. 2005. PMID: 16115483 Clinical Trial.

2

Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.

Gómez-Gerique JA, Ros E, Oliván J, Mostaza JM, Vilardell M, Pintó X, Civeira F, Hernández A, da Silva PM, Rodriguez-Botaro A, Zambón D, Lima J, Díaz C, Aristegui R, Sol JM, Chaves J, Hernández G; ATOMIX Investigators. Gómez-Gerique JA, et al. Among authors: mostaza jm. Atherosclerosis. 2002 Jun;162(2):245-51. doi: 10.1016/s0021-9150(01)00708-0. Atherosclerosis. 2002. PMID: 11996943 Clinical Trial.

3

Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy.

Lahoz C, Peña R, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M, López-Pastor A; RAP Study Group. Lahoz C, et al. Among authors: mostaza jm. Atherosclerosis. 2003 Jun;168(2):289-95. doi: 10.1016/s0021-9150(03)00094-7. Atherosclerosis. 2003. PMID: 12801612

4

[Ankle brachial index and cardiovascular risk].

Mostaza JM, Vicente I, Cairols M, Castillo J, González-Juanatey JR, Pomar JL, Lahoz C. Mostaza JM, et al. Med Clin (Barc). 2003 Jun 14;121(2):68-73. doi: 10.1016/s0025-7753(03)73857-3. Med Clin (Barc). 2003. PMID: 12828888 Review. Spanish. No abstract available.

5

[Lipid control in secondary prevention: multicenter observational study in primary care].

Brotons C, Maiques A, Mostaza J, Pintó X, Vilaseca J; Estudio EMOSCOL. Brotons C, et al. Aten Primaria. 2004 Jun 30;34(2):81-6. doi: 10.1016/s0212-6567(04)79464-0. Aten Primaria. 2004. PMID: 15225529 Free PMC article. Spanish.

6

C-reactive protein levels and prevalence of chronic infections in subjects with hypoalphalipoproteinemia.

Mostaza JM, Camino N, Gerique JG, Peña R, Baquero M, Lahoz C. Mostaza JM, et al. Metabolism. 2005 Jan;54(1):33-7. doi: 10.1016/j.metabol.2004.07.009. Metabolism. 2005. PMID: 15562377

7

[The application of the SCORE charts to advanced age males triple the number of high-risk subjects compared to the Framingham function].

Mostaza JM, Vicente I, Taboada M, Laguna F, Echániz A, García-Iglesias F, Lahoz C. Mostaza JM, et al. Med Clin (Barc). 2005 Apr 9;124(13):487-90. doi: 10.1157/13073561. Med Clin (Barc). 2005. PMID: 15847765 Spanish.

8

Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.

Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X. Lahoz C, et al. Among authors: mostaza jm. Metabolism. 2005 Jun;54(6):741-7. doi: 10.1016/j.metabol.2004.12.020. Metabolism. 2005. PMID: 15931608 Clinical Trial.

9

Metabolic syndrome and asymptomatic peripheral artery disease in subjects over 60 years of age.

Lahoz C, Vicente I, Laguna F, García-Iglesias MF, Taboada M, Mostaza JM. Lahoz C, et al. Among authors: mostaza jm. Diabetes Care. 2006 Jan;29(1):148-50. doi: 10.2337/diacare.29.1.148. Diabetes Care. 2006. PMID: 16373915 No abstract available.

10

[Risk score for diabetic patients. Is really necessary?].

Mostaza JM, Lahoz C. Mostaza JM, et al. Med Clin (Barc). 2006 Apr 8;126(13):495-6. doi: 10.1157/13086851. Med Clin (Barc). 2006. PMID: 16624229 Spanish. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Search Page

Filters